Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy☆
References (26)
Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study
Bone Miner
(1989)- et al.
The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime
Bone
(1991) - et al.
A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis
Bone
(1989) Local and systemic factors in the pathogenesis of osteoporosis
N Engl J Med
(1988)- et al.
Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
N Engl J Med
(1980) - et al.
Long-term estrogen replacement therapy prevents bone loss and fractures
Ann Intern Med
(1985) - et al.
A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
JAMA
(1991) - et al.
Long-term treatment of established osteoporosis with intranasal calcitonin
Calcif Tissue Int
(1991) Bisphosphonates—history and experimental basis
Bone
(1987)- et al.
The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate
J Lab Clin Med
(1971)
Etidronate disodium in postmenopausal osteoporosis
Clin Pharmacol Ther
(1976)
Preliminary observations of a form of coherence therapy for osteoporosis
Calcif Tissue Int
(1984)
The effect of etidronate therapy in postmenopausal osteoporotic women: preliminary results
Cited by (388)
History of alendronate
2020, BoneCitation Excerpt :However, the trials were not planned to have statistical power to detect a reduction in vertebral fracture risk. While the trials were underway, results from a trial of cyclically administered etidronate found a non-significant increase in the risk of vertebral fracture during the third year of the trial [5]. This prompted the FDA to change its guidance to require a three year duration of treatment with demonstration of a significant reduction in rates of radiographically detected vertebral fractures.
History of etidronate
2020, BoneMetabolic Bone Disease
2012, Kelley's Textbook of Rheumatology: Volume 1-2, Ninth Edition2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis
2011, Reumatologia ClinicaGuidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022)
2023, Chinese Journal of Endocrinology and MetabolismRefracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials
2023, Journal of Endocrinological Investigation
- ☆
This work was supported by a grant from Procter & Gamble Pharmaceuticals (formerly Norwich Eaton Pharmaceuticals, Inc.).
Copyright © 1983 Published by Excerpta Medica Inc.